Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with HCV genotype 1, 4, 5, or 6~* Cirrhosis determination~* Subject met the following classifications:~  * Treatment-naive~ * Screening laboratory values within defined thresholds~ * Not treated with any investigational drug or device within 30 days of screening~* Use of highly effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase~* Pregnant or nursing female, or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* History of clinically-significant illness or any other major medical disorder that may have interfered with subject treatment, assessment, or compliance with the protocol~* Excessive alcohol ingestion or significant drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+PEG+RBV (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).